AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
valbenazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5227 | 1025504-45-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The mechanism of action of valbenazine in the treatment of tardive dyskinesia is unknown, but is thought to be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 1.31 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.71 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 18 hours | Lombardo F, Berellini G, Obach RS |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,IGF1R,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MET,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ZAP70 | 42 | |||
| kinase-selectivity-class | AXL,GRK2 | 2 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 11, 2017 | FDA | NEUROCRINE BIOSCIENCES INC | |
| March 28, 2022 | PMDA | Mitsubishi Tanabe Pharma Corporation |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Somnolence | 660.09 | 36.11 | 330 | 7330 | 208754 | 90412033 |
| Drooling | 652.04 | 36.11 | 134 | 7526 | 4412 | 90616375 |
| Parkinsonism | 588.03 | 36.11 | 152 | 7508 | 13913 | 90606874 |
| Tremor | 509.82 | 36.11 | 251 | 7409 | 152922 | 90467865 |
| Dyskinesia | 334.25 | 36.11 | 123 | 7537 | 36411 | 90584376 |
| Sedation | 308.07 | 36.11 | 125 | 7535 | 48046 | 90572741 |
| Akathisia | 177.94 | 36.11 | 57 | 7603 | 11102 | 90609685 |
| Hospitalisation | 165.90 | 36.11 | 114 | 7546 | 127986 | 90492801 |
| Death | 161.12 | 36.11 | 195 | 7465 | 456356 | 90164431 |
| Tardive dyskinesia | 142.69 | 36.11 | 48 | 7612 | 10882 | 90609905 |
| Fall | 140.18 | 36.11 | 187 | 7473 | 481623 | 90139164 |
| Therapeutic product effect decreased | 139.88 | 36.11 | 143 | 7517 | 277428 | 90343359 |
| Balance disorder | 127.03 | 36.11 | 87 | 7573 | 96993 | 90523794 |
| Restlessness | 110.75 | 36.11 | 56 | 7604 | 35664 | 90585123 |
| Drug ineffective | 102.69 | 36.11 | 301 | 7359 | 1383997 | 89236790 |
| Adverse drug reaction | 95.54 | 36.11 | 79 | 7581 | 116622 | 90504165 |
| Anxiety | 87.92 | 36.11 | 119 | 7541 | 309653 | 90311134 |
| Suicidal ideation | 86.79 | 36.11 | 62 | 7598 | 73793 | 90546994 |
| Feeling abnormal | 81.96 | 36.11 | 85 | 7575 | 167150 | 90453637 |
| Dizziness | 73.82 | 36.11 | 157 | 7503 | 589127 | 90031660 |
| Bipolar disorder | 70.22 | 36.11 | 27 | 7633 | 8958 | 90611829 |
| Depression | 69.81 | 36.11 | 105 | 7555 | 300496 | 90320291 |
| Salivary hypersecretion | 66.37 | 36.11 | 26 | 7634 | 9066 | 90611721 |
| Lethargy | 62.89 | 36.11 | 48 | 7612 | 63091 | 90557696 |
| Therapeutic product effect incomplete | 60.33 | 36.11 | 78 | 7582 | 193818 | 90426969 |
| Bradykinesia | 58.83 | 36.11 | 22 | 7638 | 6766 | 90614021 |
| Nightmare | 58.51 | 36.11 | 31 | 7629 | 21694 | 90599093 |
| Urticaria | 51.99 | 36.11 | 94 | 7566 | 312640 | 90308147 |
| Gait disturbance | 49.40 | 36.11 | 83 | 7577 | 260413 | 90360374 |
| Agitation | 45.86 | 36.11 | 41 | 7619 | 67057 | 90553730 |
| Dystonia | 42.48 | 36.11 | 23 | 7637 | 16796 | 90603991 |
| Fatigue | 41.12 | 36.11 | 199 | 7461 | 1153824 | 89466963 |
| Tic | 39.87 | 36.11 | 12 | 7648 | 1899 | 90618888 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drooling | 570.12 | 40.58 | 120 | 3735 | 4179 | 42613301 |
| Parkinsonism | 357.44 | 40.58 | 98 | 3757 | 10525 | 42606955 |
| Somnolence | 310.13 | 40.58 | 179 | 3676 | 140926 | 42476554 |
| Tremor | 244.99 | 40.58 | 135 | 3720 | 96794 | 42520686 |
| Sedation | 166.30 | 40.58 | 72 | 3783 | 30403 | 42587077 |
| Hospitalisation | 133.09 | 40.58 | 83 | 3772 | 74247 | 42543233 |
| Dyskinesia | 125.54 | 40.58 | 56 | 3799 | 25334 | 42592146 |
| Therapeutic product effect decreased | 116.61 | 40.58 | 61 | 3794 | 39089 | 42578391 |
| Anxiety | 90.10 | 40.58 | 79 | 3776 | 118481 | 42498999 |
| Suicidal ideation | 79.11 | 40.58 | 51 | 3804 | 48110 | 42569370 |
| Fall | 78.67 | 40.58 | 101 | 3754 | 234419 | 42383061 |
| Adverse drug reaction | 77.64 | 40.58 | 46 | 3809 | 37388 | 42580092 |
| Restlessness | 74.21 | 40.58 | 41 | 3814 | 29208 | 42588272 |
| Drug ineffective | 73.35 | 40.58 | 169 | 3686 | 630028 | 41987452 |
| Death | 69.17 | 40.58 | 139 | 3716 | 471046 | 42146434 |
| Balance disorder | 55.85 | 40.58 | 41 | 3814 | 47604 | 42569876 |
| Akathisia | 54.64 | 40.58 | 24 | 3831 | 10427 | 42607053 |
| Dizziness | 53.58 | 40.58 | 87 | 3768 | 249167 | 42368313 |
| Agitation | 45.04 | 40.58 | 41 | 3814 | 64273 | 42553207 |
| Lethargy | 43.23 | 40.58 | 35 | 3820 | 46855 | 42570625 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drooling | 623.05 | 37.63 | 135 | 7577 | 7004 | 110574583 |
| Parkinsonism | 562.16 | 37.63 | 155 | 7557 | 22032 | 110559555 |
| Somnolence | 540.94 | 37.63 | 305 | 7407 | 297144 | 110284443 |
| Tremor | 474.94 | 37.63 | 246 | 7466 | 201986 | 110379601 |
| Dyskinesia | 281.21 | 37.63 | 113 | 7599 | 51333 | 110530254 |
| Sedation | 254.51 | 37.63 | 115 | 7597 | 69568 | 110512019 |
| Death | 208.50 | 37.63 | 249 | 7463 | 698620 | 109882967 |
| Hospitalisation | 197.23 | 37.63 | 123 | 7589 | 142370 | 110439217 |
| Fall | 157.03 | 37.63 | 201 | 7511 | 603281 | 109978306 |
| Anxiety | 138.63 | 37.63 | 144 | 7568 | 344934 | 110236653 |
| Tardive dyskinesia | 133.70 | 37.63 | 46 | 7666 | 13533 | 110568054 |
| Restlessness | 133.04 | 37.63 | 69 | 7643 | 56190 | 110525397 |
| Akathisia | 116.04 | 37.63 | 44 | 7668 | 17069 | 110564518 |
| Balance disorder | 116.02 | 37.63 | 82 | 7630 | 116478 | 110465109 |
| Suicidal ideation | 100.27 | 37.63 | 69 | 7643 | 93868 | 110487719 |
| Therapeutic product effect decreased | 87.42 | 37.63 | 96 | 7616 | 244220 | 110337367 |
| Feeling abnormal | 77.06 | 37.63 | 78 | 7634 | 180633 | 110400954 |
| Lethargy | 75.41 | 37.63 | 58 | 7654 | 93518 | 110488069 |
| Depression | 71.84 | 37.63 | 99 | 7613 | 317236 | 110264351 |
| Dizziness | 68.14 | 37.63 | 150 | 7562 | 698043 | 109883544 |
| Adverse drug reaction | 67.19 | 37.63 | 57 | 7655 | 105502 | 110476085 |
| Salivary hypersecretion | 64.27 | 37.63 | 29 | 7683 | 17392 | 110564195 |
| Gait disturbance | 63.25 | 37.63 | 87 | 7625 | 278121 | 110303466 |
| Urticaria | 58.37 | 37.63 | 90 | 7622 | 318767 | 110262820 |
| Fatigue | 51.30 | 37.63 | 193 | 7519 | 1215765 | 109365822 |
| Drug ineffective | 51.24 | 37.63 | 225 | 7487 | 1520315 | 109061272 |
| Agitation | 48.52 | 37.63 | 49 | 7663 | 113002 | 110468585 |
| Dystonia | 47.97 | 37.63 | 27 | 7685 | 25778 | 110555809 |
| Therapeutic product effect incomplete | 46.40 | 37.63 | 67 | 7645 | 223738 | 110357849 |
| Bradykinesia | 46.38 | 37.63 | 20 | 7692 | 10768 | 110570819 |
| Bipolar disorder | 39.72 | 37.63 | 17 | 7695 | 8990 | 110572597 |
| Insomnia | 39.10 | 37.63 | 81 | 7631 | 360509 | 110221078 |
| Depressed mood | 39.00 | 37.63 | 33 | 7679 | 60776 | 110520811 |
| Nightmare | 37.82 | 37.63 | 27 | 7685 | 38836 | 110542751 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N07XX13 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS OTHER NERVOUS SYSTEM DRUGS Other nervous system drugs |
| FDA MoA | N0000190855 | Vesicular Monoamine Transporter 2 Inhibitors |
| FDA EPC | N0000190856 | Vesicular Monoamine Transporter 2 Inhibitor |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
Related Drugs by ATC class:
N07XX Other nervous system drugs 23 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Tardive dyskinesia | indication | 102449007 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.25 | Basic |
| pKa2 | 7.56 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11439629 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11439629 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11439629 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11439629 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11439629 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11439629 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11654142 | Nov. 14, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11654142 | Nov. 14, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11654142 | Nov. 14, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11654142 | Nov. 14, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11654142 | Nov. 14, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11654142 | Nov. 14, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | Aug. 18, 2026 | TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTON’S DISEASE |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | Aug. 18, 2026 | TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTON’S DISEASE |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | Aug. 18, 2026 | TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTON’S DISEASE |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | Aug. 18, 2026 | TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTON’S DISEASE |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | Aug. 18, 2026 | TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTON’S DISEASE |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | Aug. 18, 2026 | TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTON’S DISEASE |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | Aug. 18, 2030 | FOR TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | Aug. 18, 2030 | FOR TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | Aug. 18, 2030 | FOR TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Synaptic vesicular amine transporter | Transporter | INHIBITOR | Ki | 8.52 | DRUG LABEL | DRUG LABEL | |||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.77 | CHEMBL | |||||
| Synaptic vesicular amine transporter | Transporter | INHIBITOR | Ki | 6.73 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 54K37P50KH | UNII |
| 1639208-54-0 | SECONDARY_CAS_RN |
| 4036639 | VANDF |
| C4078701 | UMLSCUI |
| CHEBI:754993 | CHEBI |
| XW7 | PDB_CHEM_ID |
| CHEMBL2364639 | ChEMBL_ID |
| 24795069 | PUBCHEM_CID |
| DB11915 | DRUGBANK_ID |
| D10675 | KEGG_DRUG |
| CHEMBL3707248 | ChEMBL_ID |
| 9744 | INN_ID |
| C000603978 | MESH_SUPPLEMENTAL_RECORD_UI |
| 8694 | IUPHAR_LIGAND_ID |
| 733727001 | SNOMEDCT_US |
| 763512007 | SNOMEDCT_US |
| 255701 | MMSL |
| 32624 | MMSL |
| d08559 | MMSL |
| 14580381 | PUBCHEM_CID |
| 017167 | NDDF |
| 017168 | NDDF |
| 1918219 | RXNORM |
| 54K37P50KH | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1060 | CAPSULE | 60 mg | ORAL | NDA | 33 sections |
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1060 | CAPSULE | 60 mg | ORAL | NDA | 33 sections |
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1080 | CAPSULE | 80 mg | ORAL | NDA | 33 sections |
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1080 | CAPSULE | 80 mg | ORAL | NDA | 33 sections |
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-2040 | CAPSULE | 40 mg | ORAL | NDA | 33 sections |
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-2040 | CAPSULE | 40 mg | ORAL | NDA | 33 sections |
| INGREZZA Sprinkle | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-4040 | CAPSULE | 40 mg | ORAL | NDA | 33 sections |
| INGREZZA Sprinkle | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-4040 | CAPSULE | 40 mg | ORAL | NDA | 33 sections |
| INGREZZA Sprinkle | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-4060 | CAPSULE | 60 mg | ORAL | NDA | 33 sections |
| INGREZZA Sprinkle | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-4060 | CAPSULE | 60 mg | ORAL | NDA | 33 sections |
| INGREZZA Sprinkle | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-4080 | CAPSULE | 80 mg | ORAL | NDA | 33 sections |
| INGREZZA Sprinkle | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-4080 | CAPSULE | 80 mg | ORAL | NDA | 33 sections |